{ "release_id": "5dcd9b263fe17744", "id": "cardio:lipoprotein-a", "owner": "cardio", "kind": "biomarker", "slug": "lipoprotein-a", "name": "Lipoprotein(a)", "aliases": [ "Lp(a)" ], "atlases": [ "cardio" ], "summary_plain": "Lipoprotein(a), written Lp(a), is a cholesterol-carrying particle in the blood. Novartis says its level is about 90% set by genes and little changed by diet or lifestyle. In September 2026 Novartis reported that a large outcomes trial of pelacarsen, a medicine that lowers Lp(a), did not meet its main goal of reducing heart events.", "summary_technical": "The Lp(a)HORIZON registry record (NCT04023552) lists the condition as Cardiovascular Disease and Lipoprotein(a). On 4 September 2026 Novartis announced that the trial missed its primary endpoint (see the claim), so Lp(a) lowering with pelacarsen has not been shown to lower cardiovascular events. The full data had not been presented when this record was written. The 90% figure is a sponsor statement in a press release. MeSH has a heading for the particle.", "editorial_state": "draft", "last_substantive_edit": "2026-10-14", "last_evidence_check": "2026-10-14", "next_review_due": null, "identifiers": [ { "scheme": "mesh", "value": "D017270", "normalized_value": "D017270", "match": "exact", "version": "MeSH linked-data descriptor record fetched on 2026-10-14, lastUpdated 2006-07-05; the record states no yearly MeSH release", "label": null, "from_source": false } ], "navigation": { "cardio": { "system": [ "metabolism" ], "condition-area": [ "coronary-and-vascular-disease" ] } }, "payload": { "measure": "Concentration of lipoprotein(a) in blood; the Lp(a)HORIZON sponsor describes thresholds of 70 and 90 mg/dL", "assay_context": "Blood test. The sources read give no assay details.", "interpretation_claims": [ "cardio:claim-lpa-horizon-pelacarsen-topline-null" ] }, "content_digest": "65850b154af6a81d57a8594100f37fb053916df5ac72574b69e3f9d81b659606", "review": { "content_digest": "65850b154af6a81d57a8594100f37fb053916df5ac72574b69e3f9d81b659606", "current": [], "conflicting": [], "stale": [], "inactive": [] }, "claims": [ { "release_id": "5dcd9b263fe17744", "id": "cardio:claim-lpa-horizon-pelacarsen-topline-null", "owner": "cardio", "subject_entity_id": "cardio:lipoprotein-a", "category": "effect", "statement": "Novartis reported topline results on 4 September 2026 for Lp(a)HORIZON, a phase 3 outcomes trial of pelacarsen in adults with elevated Lp(a) and established cardiovascular disease: pelacarsen, compared with placebo, missed the trial primary endpoint, a four-part composite of cardiovascular death, heart attack, stroke and urgent coronary revascularization with hospital admission. Lp(a) fell on pelacarsen, but across all participants this was not shown to cut cardiovascular risk. The release gives no numbers and says full results will be shown at a future scientific meeting. The registry lists 8323 participants and completion on 2026-07-16.", "context": { "id": "cardio:ctx-lpa-horizon-elevated-lpa-established-cvd", "label": "Adults with elevated Lp(a) and established cardiovascular disease (Lp(a)HORIZON)", "recipient": "adult", "population": "Patients with elevated Lp(a) and established cardiovascular disease. Novartis describes two analysis populations for the primary endpoint: everyone with Lp(a) of 70 mg/dL or more, and a subgroup with 90 mg/dL or more. The registry gives ages 18 to 80 years and enrollment of 8323.", "care_setting": "Global multicentre trial per the sponsor; site list not read", "geography": "Global (sponsor wording); countries not read", "life_stage_note": "Adult, 18 to 80 years (registry)", "life_stage_terms": null, "gestational_age_min_days": null, "gestational_age_max_days": null, "gestational_age_basis": null, "postnatal_age_min_days": null, "postnatal_age_max_days": null, "gestational_age_status": null, "postnatal_age_status": null, "followup_description": "Not stated in the sources read. The registry gives completion on 2026-07-16.", "eligibility": { "inclusion": [ "Elevated Lp(a)", "Established cardiovascular disease" ], "exclusion": [] } }, "evidence_stage": "interventional", "certainty": "not_assessed", "certainty_method": null, "limitations": "This is a sponsor topline press release, not a peer-reviewed paper, and it gives no counts, hazard ratios or intervals. A PubMed title search on 2026-10-14 found commentary but no results paper (fetch log rows cg-status-pubmed-lpahorizon.json and cg-status-pubmed-summary.json). The release reports no separate result for the subgroup with Lp(a) of 90 mg/dL or more, although the primary endpoint was defined in both the overall population and that subgroup. The result may be refined when the full data are presented. The finding is for pelacarsen, one Lp(a)-lowering medicine, in people with established disease, and does not by itself settle whether other Lp(a)-lowering approaches would work.", "editorial_state": "draft", "checked_at": "2026-10-14", "next_review_due": null, "valid_from": null, "valid_to": null, "citations": [ { "evidence_role": "supports", "locator": "Press release, paragraph 1, sentence 1 (endpoint statement, first part)", "applicability_note": "Sponsor statement of the result and the first part of the composite.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "supports", "locator": "Press release, paragraph 1, sentence 1 (endpoint statement, second part)", "applicability_note": "Rest of the primary endpoint wording.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "supports", "locator": "Press release, paragraph 1, sentence 2", "applicability_note": "Lp(a) lowering reported by the sponsor.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "supports", "locator": "Press release, paragraph 2, statement of the Chief Medical Officer", "applicability_note": "Sponsor interpretation.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "supports", "locator": "Press release, paragraph 3", "applicability_note": "Full data not yet released.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "supports", "locator": "Press release, dateline", "applicability_note": "Date of the statement.", "snapshot": { "id": "cardio:novartis-lpahorizon-topline-2026-10-14", "retrieved_at": "2026-10-14T18:26:10Z", "content_hash": "c334fcc8d8fe02bf04a340a71b88a0e3843f160501677562aab5dd978e5469ad", "source_effective_date": "2026-09-04", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:novartis-lpahorizon-topline", "source_type": "webpage", "title": "Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)", "canonical_url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd", "identifiers": [], "publication_date": null, "publisher": "Novartis AG (company press release)", "edition": "Ad hoc announcement dated Basel, September 4, 2026. Page fetched 2026-10-14. A sponsor statement, not a peer-reviewed report: it gives no result numbers.", "reuse_basis": "Company press release. Its reuse terms were not read, so they are unverified. Only the hash of the page is kept, and public text is cite_only: facts are stated in the atlas's own words with a link.", "public_text": "cite_only" } }, { "evidence_role": "context", "locator": "protocolSection.identificationModule.officialTitle: \"A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230)\"", "applicability_note": "Registry title: placebo-controlled, double-blind.", "snapshot": { "id": "cardio:ctgov-nct04023552-2026-10-14", "retrieved_at": "2026-10-14T18:18:40Z", "content_hash": "f07058e6a56963b4a23bf9927f9651d03a4ed25bf48234708ac8dc88e1ede929", "source_effective_date": "2026-08-28", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:ctgov-nct04023552", "source_type": "registry", "title": "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD", "canonical_url": "https://clinicaltrials.gov/study/NCT04023552", "identifiers": [ { "scheme": "nct", "value": "NCT04023552", "normalized_value": "NCT04023552", "match": "exact", "version": null, "label": null, "from_source": false } ], "publication_date": null, "publisher": "U.S. National Library of Medicine (ClinicalTrials.gov)", "edition": "ClinicalTrials.gov API v2 record, last update posted 2026-08-28.", "reuse_basis": "Registry record. The raw API JSON is committed. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read by a script, so the redistribution basis is unverified; any quotation stays short. The raw file is committed at research/snapshots/cg-ctgov-NCT04023552.json.", "public_text": "quote" } }, { "evidence_role": "context", "locator": "protocolSection.identificationModule.officialTitle: \"on Major Cardiovascular Events in Patients With Established Cardiovascular Disease\"", "applicability_note": "Registry title, population.", "snapshot": { "id": "cardio:ctgov-nct04023552-2026-10-14", "retrieved_at": "2026-10-14T18:18:40Z", "content_hash": "f07058e6a56963b4a23bf9927f9651d03a4ed25bf48234708ac8dc88e1ede929", "source_effective_date": "2026-08-28", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:ctgov-nct04023552", "source_type": "registry", "title": "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD", "canonical_url": "https://clinicaltrials.gov/study/NCT04023552", "identifiers": [ { "scheme": "nct", "value": "NCT04023552", "normalized_value": "NCT04023552", "match": "exact", "version": null, "label": null, "from_source": false } ], "publication_date": null, "publisher": "U.S. National Library of Medicine (ClinicalTrials.gov)", "edition": "ClinicalTrials.gov API v2 record, last update posted 2026-08-28.", "reuse_basis": "Registry record. The raw API JSON is committed. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read by a script, so the redistribution basis is unverified; any quotation stays short. The raw file is committed at research/snapshots/cg-ctgov-NCT04023552.json.", "public_text": "quote" } }, { "evidence_role": "supports", "locator": "protocolSection.designModule.enrollmentInfo.count: \"8323\"", "applicability_note": "Registry enrollment count.", "snapshot": { "id": "cardio:ctgov-nct04023552-2026-10-14", "retrieved_at": "2026-10-14T18:18:40Z", "content_hash": "f07058e6a56963b4a23bf9927f9651d03a4ed25bf48234708ac8dc88e1ede929", "source_effective_date": "2026-08-28", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:ctgov-nct04023552", "source_type": "registry", "title": "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD", "canonical_url": "https://clinicaltrials.gov/study/NCT04023552", "identifiers": [ { "scheme": "nct", "value": "NCT04023552", "normalized_value": "NCT04023552", "match": "exact", "version": null, "label": null, "from_source": false } ], "publication_date": null, "publisher": "U.S. National Library of Medicine (ClinicalTrials.gov)", "edition": "ClinicalTrials.gov API v2 record, last update posted 2026-08-28.", "reuse_basis": "Registry record. The raw API JSON is committed. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read by a script, so the redistribution basis is unverified; any quotation stays short. The raw file is committed at research/snapshots/cg-ctgov-NCT04023552.json.", "public_text": "quote" } }, { "evidence_role": "supports", "locator": "protocolSection.statusModule.completionDateStruct.date: \"2026-07-16\"", "applicability_note": "Registry completion date.", "snapshot": { "id": "cardio:ctgov-nct04023552-2026-10-14", "retrieved_at": "2026-10-14T18:18:40Z", "content_hash": "f07058e6a56963b4a23bf9927f9651d03a4ed25bf48234708ac8dc88e1ede929", "source_effective_date": "2026-08-28", "public_archive_url": null, "source_state": "current" }, "source": { "id": "cardio:ctgov-nct04023552", "source_type": "registry", "title": "Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD", "canonical_url": "https://clinicaltrials.gov/study/NCT04023552", "identifiers": [ { "scheme": "nct", "value": "NCT04023552", "normalized_value": "NCT04023552", "match": "exact", "version": null, "label": null, "from_source": false } ], "publication_date": null, "publisher": "U.S. National Library of Medicine (ClinicalTrials.gov)", "edition": "ClinicalTrials.gov API v2 record, last update posted 2026-08-28.", "reuse_basis": "Registry record. The raw API JSON is committed. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read by a script, so the redistribution basis is unverified; any quotation stays short. The raw file is committed at research/snapshots/cg-ctgov-NCT04023552.json.", "public_text": "quote" } } ], "review": { "content_digest": "5b0ecce985d374f938d985488a6473162173e332db5edfca912e6ab0db1c6753", "current": [], "conflicting": [], "stale": [], "inactive": [] }, "api_path": "api/v1/claims/cardio--claim-lpa-horizon-pelacarsen-topline-null.json" } ], "decisions": [], "milestones": [], "relationships": { "outgoing": [ { "predicate": "related_to", "label": "Under study as a separate cause", "clinical_claim_not_fact": false, "family": "navigation", "other_entity_id": "cardio:coronary-artery-disease", "other_entity_in_atlas": true, "claim_id": null, "evidence": null, "primary": false, "role": null, "valid_from": null, "valid_to": null } ], "incoming": [] }, "page_path": "biomarkers/lipoprotein-a/", "context_path": "api/v1/context/cardio--lipoprotein-a.md" }